- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Innovative Drug, Biologic, and Device Development
Events 17 results
Speaking Engagement
June 28, 2022
Tamra Moore to Speak on AI for Health Equity Virtual Symposium 2022
Speaking Engagement
June 28, 2022
Eva Temkin to Interview M. Stacey Ricci About Biosimilars and Interchangeable Products
Speaking Engagement
June 27, 2022
Tamra Moore to Speak at American Society of Health Economists Conference
Speaking Engagement
June 14, 2022
Eva Temkin to Speak at Food and Drug Law Institute
Speaking Engagement
May 19, 2022
Eva Temkin to Speak at Rare Disease Innovation & Partnering Summit
Speaking Engagement
March 16, 2022
Eva Temkin, Chris Markus to Speak at Food and Drug Law Institute’s Conference About Biological Products
Speaking Engagement
December 15, 2021
Eva Temkin, Elaine Tseng to Speak at AFDLI Food and Drug Law Institute Conference
Speaking Engagement
November 10, 2021
Eva Temkin to Speak at GRx+Biosims Generics + Biosimilars Conference
Webinar
November 9, 2021
King & Spalding Pharmaceutical University 2021
Speaking Engagement
October 13, 2021
Eva Temkin to Speak at Food and Drug Law Institute’s Advertising and Promotion for Medical Products Conference
Speaking Engagement
October 5, 2021
Eva Temkin to Speak at DIA Biosimilars Conference
Speaking Engagement
June 25, 2021
Eva Temkin to Speak at CE Synergy’s 1st Annual Advanced Topics for Oncology Pharmacy Professionals Summit